Abstract: The present invention provides a humanized anti-HMGB1 antibody which specifically binds to a sequence consisting of the C-terminal 8 amino acid residues (EEEDDDDE) of HMGB1 protein and is effective for treatment or prevention of various inflammatory diseases related to this protein, as well as an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising such an antibody or antigen-binding fragment thereof.
Type:
Grant
Filed:
December 6, 2013
Date of Patent:
January 24, 2017
Assignees:
EVEC INC., NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
Abstract: Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.
Type:
Application
Filed:
January 28, 2014
Publication date:
July 24, 2014
Applicants:
Boehringer Ingelheim International GmbH, Evec Inc.
Inventors:
Kenzo Takada, Kantou Nakajima, John Park, Barbara Kistler
Abstract: Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.
Type:
Grant
Filed:
November 12, 2008
Date of Patent:
March 25, 2014
Assignees:
Evec Inc., Boehringer Ingelheim International GmbH
Inventors:
Kenzo Takada, Kantou Nakajima, Barbara Kistler, John Park
Abstract: Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.
Type:
Application
Filed:
November 12, 2008
Publication date:
July 28, 2011
Applicants:
Evec Inc., Boehringer Ingelheim International GmbH
Inventors:
Kenzo Takada, Kantou Nakajima, Barbara Kistler, John Park
Abstract: The present invention provides a human monoclonal antibody, and antigen-binding portions thereof, capable of binding to human granulocyte-macrophage colony stimulating factor (hGM-CSF) and neutralizing the bioactivity of the hGM-CSF, wherein the anti-hGM-CSF monoclonal antibody has a light chain (L chain) including an amino acid sequence SEQ ID NO:1 and a heavy chain (H chain) including an amino acid sequence SEQ ID NO: 2. Also provided are human monoclonal anti-hGM-CSF antibodies, and antigen-binding portions thereof, characterized by complementarity determining regions (CDRs) or H chain and L chain variable regions related to SEQ ID NO:1 and SEQ ID NO:2. Antibodies, and antigen-binding portions thereof, of the invention are useful in the treatment of diseases associated with overproduction of hGM-CSF, including allergic disease, graft rejection and graft-versus-host disease (GVHD), and autoimmune diseases.